Trials / Completed
CompletedNCT05188521
Baricitinib (LY3009104) in the Treatment of Cutaneous Lichen Planus
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 12 (actual)
- Sponsor
- Aaron R. Mangold · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This research study is evaluating the safety and efficacy of Baricitinib in treating Cutaneous Lichen Planus (LP).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Baricitinib (LY3009104) 2 mg | 2 mg orally administered once daily for 16 weeks |
| DRUG | Baricitinib (LY3009104) 4 mg | 4 mg orally administered once daily for 12 weeks |
Timeline
- Start date
- 2022-01-11
- Primary completion
- 2023-05-17
- Completion
- 2023-05-17
- First posted
- 2022-01-12
- Last updated
- 2024-06-11
- Results posted
- 2024-06-11
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05188521. Inclusion in this directory is not an endorsement.